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ABSTRACT
Objectives: The aim of this study was to determine the effect of drug-related problems (DRPs) on the decrease in hemoglobin levels in cancer patients.
Methods: This study was a prospective cross-sectional study on seven cancer patients at Haji Adam Malik (HAM) Hospital. Patients aged 35 years 
old and above with any cancer type and stage from April 2017 to July 2017 were included in the study at HAM Hospital Medan. DRPs were analyzed 
using DRP Registration Form V7.0 Pharmaceutical Care Network Europe. The obtain data were tested using Chi-square test (p<0.05 is considered 
significant).
Results: The result showed that based on the characteristics of age, the largest group was 46–55 years, and based on the suffered stage, the most stage 
was Stage III with 57.14%. Two DRPs were identified in seven patients. The most prevalent DRPs were the interaction of drug (100%) followed by 
unwanted drug reaction (85.71%) and the risk of DRPs was decreasing the hemoglobin levels in cancer patients from the median-to-moderate levels.
Conclusion: Drug-related problems are common among cancer patients. Interaction of drug problems and unwanted drug reaction were the most 
common types of DRPs among cancer patients, and showed that there was a relationship of DRPs on the decrease in hemoglobin levels.
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INTRODUCTION
Cancer is a disease caused by the growth of cells of body tissue that is 
not normal. Cancer cells will attack and destroy other biological tissues, 
either by direct growth in adjacent tissue (invasion) or by migrating 
cells to distant sites (metastases) [1].
Cancer has become a global burden because of the aging, increased 
adoption of cancer-causing behaviors particularly smoking and 
exposure to triggering factors such as chemicals, radiations, unhealthy 
eating habits, and a sedentary lifestyle. Different modalities for 
treatment of cancer include radiation, surgery, chemotherapy, hormonal 
therapy, immunotherapy, biologic therapy, and cryosurgery [2]. The 
treatments with cancer chemotherapeutic drugs are often associated 
with a variety of serious and non-serious drug-related problems 
(DRPs). The most common side effect of chemotherapy administration 
is nausea with or without vomiting, diarrhea, alopecia, darkening 
of skin and nails, darkening of the injection site, myelosuppression, 
mucositis, neuropathy, cardiomyopathy, and electrolyte imbalance [3].
Drugs are widely used because of their ability to affect the biological systems 
of the body. The use of these drugs may also certain unwanted or unintended 
effects. Each time a patient is exposed to a drug it cannot be certained about 
the unwanted effects of the product. However, we can learn from previous 
experience where patients have been exposed to the similar drug [4].
DRPs are defined as an event or circumstance involving medication 
therapy that actually or potentially interferes with an optimum 
outcome for a specific patient [5]. One of the effects of chemotherapy 
is the formation of free radicals doxorubicin. Excessive free radicals 
are toxic and will damage normal cells including bone marrow cells 
resulting in suppression of the red blood cell forming system that 
produces hemoglobin [6].
Despite the significance of DRPs, published information on DRPs in the 
patients with cancer is frequent. This study is part of our continuous effort 
to review the updated data on the common DRP detected by pharmacists 
in cancer patients receiving chemotherapy, the common drugs involved, 
and the common actions taken to resolve the DRPs detected.
METHODS
Study design and patients
This was a prospective cross-sectional study on cancer patients. 
Patients aged 35 years old and above with any cancer type and stage 
from April 2017 to July 2017 were included in the study. Patients were 
excluded from the study if the reports were incomplete.
Data collection
Patients’ demographic data, medical information, medication list, 
number and type of DRPs detected, drugs involved, and actions taken to 
resolve DRPs were retrieved from the database at RSUP Haji Adam Malik.
Classification of drug-related problems
The American Society of Hospital Pharmacists classification system for 
DRP was modified for this study [7]. DRPs identified by pharmacists were 
documented and categorized into some categories, namely, indication 
without drug or more medication required, drug without indication or 
discontinuation of medication required, wrong drug or inappropriate 
drug, overdose or duplication, underdose, non-adherence, adverse drug 
events, potential drug-drug interaction, and others.
Statistical analysis
Chi-square tests were performed to examine the associations of patient 
factors such as age, gender, number of chronic medications, and number 
of comorbid conditions with the presence or absence of DRPs, and the 
effects of related factors on DRP were also evaluated by it. Statistical 
significance was set at p≤0.05, and all statistical analyses were performed 
using Statistical Package for the Social Sciences (SPSS) version 21.
RESULTS
There were 7 patients who participated in this study from April 2017 to 
July 2017. The sex of cancer patients consisted of male patients as many 
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as 1 patient (14.29%) and female patients as many as 6 patients (85.71%). 
Most cancer patients between the ages of 46–55 years, that is, 4 patients 
(57.14%), age between 35 and 45 years, that is, 2 patients (28.57%), and 
the number of patients aged between 56 and 65 years, that is, 1 patient 
(14.28%). The number of Stage III cancer patients were 4 patients 
(57.14%), and Stage IV were 3 patients (42.85%). That the cancer patients 
who underwent the chemotherapy Cycle I–IV were 3 patients (42.85%), 
and the chemotherapy Cycle V–VIII were 4 patients (57.14%).
Drug-related problems
The most common DRPs criteria were medication interaction with 
treatment were 7 patients (100.00%), and DRPs on unwanted drug 
reactions were 6 patients (85.71%).
DISCUSSION
Drug-related problems are prevalent among cancer patients receiving 
chemotherapy as at least one DRP was detected in 100% of the patients 
in this study. This finding is consistent with the study undertaken by 
Yeoh et al. on the local patients with cancer, which reported 91.5% of 
the patients with at least one DRPs.
In aging there is a decrease in the function of cells and tissues in 
maintaining the structure and repair itself so the accumulation of cell 
damage. Hence, gradually the immune system decreases, so there are 
many metabolic distortions that cause the emergence of degenerative 
diseases and age-related diseases such as cancer. The most cancer 
patients first detected is in Stage III. This is probably due to the patient’s 
unaware of cancer characteristics and the absence of the patient’s 
perceived grievances during Stage I and Stage II [9].
The occurrence of decreased hemoglobin levels due to doxorubicin 
chemotherapy is the formation of free radicals doxorubicin. Excessive 
free radicals are toxic that will damage normal cells including bone 
marrow cells resulting in suppression of blood cell forming systems 
that produce hemoglobin [6].
Malignancy causes the life of red blood cells to be shorter, causing the 
hormone-forming erythrocytes (red blood cells) to decrease, resulting 
in a decrease in hemoglobin [10]. This decrease in hemoglobin 
levels describes the effect of doxorubicin and its combination during 
chemotherapy, in addition to cancer malignancy is also a factor in 
decreasing hemoglobin levels [11].
CONCLUSION
DRPs are significant among patients receiving chemotherapy. Potential 
drug-drug interaction, adverse drug events, and cancer’s cycle were 
the most common DRPs detected in this study. The common actions 
taken to resolve the detected DRPs include increased monitoring and 
patient education. Characterizing the common DRPs detected, the study 
provides health-care professionals greater insight into the DRP affecting 
patients with cancer and hopes to increase awareness, promote early 
detection of DRPs, and guide the formulation of appropriate DRPs 
management strategies, thereby improving the patient care at risk for 
DRPs.
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Table 1: Patient baseline characteristics
